ABSTRACT. The ELISA we developed was able to determine the antigen content and was suitable for a potency test, and we described a relative potency assay method which determines the potency of test vaccines by comparing the ELISA value of a test vaccine to that of a reference vaccine. In the present study, we standardized the reference vaccine used for determining the potencies of test vaccines, and established a potency test by ELISA. We evaluated the proposed reference vaccine by the neutralizing antibody responses in dogs after vaccination, by the challenge protection test in guinea pigs (GP potency test), which is the earlier official potency test used in Japan, and by the NIH potency test, which is widely used throughout the world. The results showed that a 4-fold dilution of the proposed reference vaccine induced sufficient immunity in dogs. A 3-fold dilution of the proposed reference vaccine passed the GP potency test. The international units (IU) calibrated by the NIH potency test were 3.7 IU/dose. From the results and the WHO recommendation that veterinary rabies vaccines should have a potency of at least 1.0 IU/dose, we determined to dilute the proposed reference vaccine by 3 fold and regarded it as the reference vaccine. Finally, we confirmed that there is a good agreement between the results of the potency test by ELISA and the results of the GP potency test. The establishment of the potency test by ELISA has made it possible to monitor the potency in the production process and has contributed to the stable production of the vaccine. KEY WORDS: ELISA, potency test, rabies vaccine.
Japan has been free from rabies since 1957. Compulsory vaccination has played an important role in eradicating and controlling rabies. The Pharmaceutical Affairs Law requires that veterinary biologicals, including rabies vaccines, be approved by the national authority in order to confirm quality, safety and efficacy. The official potency test for rabies vaccines for animal use in Japan had been a challenge protection test on guinea pigs (GP potency test), a more advanced potency test than the NIH potency test [7] , which is widely used throughout the world. In the GP potency test, a single vaccination by the subcutaneous route, the same as that used for dogs, is performed. The intramuscular challenge route is similar to that of natural infection in the field, but this test still has several disadvantages; for example, it is time consuming, gives various results and requires the use of many animals [1] .
In vitro assays for quantification of the protective antigen in rabies vaccine are recommended by WHO as an alternative potency test for a rabies vaccine [8] . Those assays do not take much time and enable determination of the quantity of the antigen in the production process. They are also biohazard-safe and do not violate animal welfare. We have been working on the development of an ELISA as a quick, sensitive and simple method to test the potency of rabies vaccines.
We previously reported that ELISA was suitable as a potency test for rabies vaccines [2] . The protective antigen content in rabies vaccines and the ELISA value were dosedependent, the dependence being linear. And the relationship between the protective antigen content in rabies vaccines measured by the ELISA and the neutralizing antibody response in guinea pigs corresponding to the content of each antigen immunized was close.
We then tried to establish a potency test by ELISA for determining potencies of test vaccines in comparison with a reference vaccine. We previously reported a relative potency test method that involved two parallel tests with 3 doses by using a reference vaccine. The reference vaccine also ensures the reliability and reproducibility of the ELISA. Since the Rabies Prevention Law in Japan requires that dogs be injected with rabies vaccines every year, the prerequisite of the reference vaccine is an induction of sufficient immunity in the dog to last one year protecting against infection. Ishikawa and others [5] investigated the relationship between challenge protection and neutralizing antibodies induced by the vaccine and found that dogs with a neutralizing antibody titer of 10 or more were able to endure the challenge. Therefore, we evaluated the proposed reference vaccine by the neutralizing antibody responses. In addition, the reference vaccine should pass the GP potency test and should meet the potency requirement recommended by WHO [9] .
MATERIALS AND METHODS

Rabies vaccines:
Rabies vaccines produced by six manufacturers in Japan [5, 6] were examined in this study. Each rabies vaccine was produced by a seed lot system. Briefly, the RC-HL strain [6] of rabies virus was propagated in HmLu cells at 34°C for 5 days. The supernatant was con-centrated with polyethylene glycol, resuspended in phosphate-buffered saline (PBS), and inactivated with betapropiolactone. The protein content has to be equal to or less than 0.1 mg/ml.
Proposed reference vaccine: The proposed reference vaccine, which is a freeze-dried vaccine derived from the RC-HL strain, was produced especially for use as the reference material and has a higher virus concentration than those of commercial vaccines. The proposed reference vaccine was dissolved in 6 ml of a diluent.
ELISA: The ELISA technique was based on an antibodybinding method with a monoclonal antibody to the glycoprotein of the rabies virus as described previously [2] . This ELISA enables determination of the antigen content in the vaccine, which was found to be closely correlated with the ELISA value.
Method for calculating relative potency: The potencies of test vaccines were determined by the relative potency assay, which involves two parallel assays with 3 doses by using the reference vaccine as described previously [3] . In this method, a relative potency (RP) of 0.683 or higher is regarded as a pass.
Examination of neutralizing antibody response in dogs after vaccination:
The immunogenicity of the proposed reference vaccine in dogs was examined by neutralizing antibody responses after vaccination. Eighty-seven dogs (2-21 month old) kept at six facilities that had never been injected with rabies vaccines were injected with dilutions of the proposed reference vaccine. The dogs were divided into 3 groups; those injected with undiluted proposed reference vaccine, those injected with the proposed reference vaccine diluted 2 fold, and those injected with the proposed reference vaccine diluted 4 fold. Each dog was bled at 1, 3, 6 and 12 months after vaccination, and the sera were stored at -20°C. The serum neutralizing antibody values were determined by the indirect immunoperoxidase technique as described previously [4] . Anti-rabies virus guinea pig serum and peroxidase-conjugated anti-guinea pig IgG rabbit sera were used as the first and the second sera, respectively. The neutralizing antibody values were expressed as the reciprocal of the serum dilution that inhibited coloration of more than 50% of the inoculated wells.
NIH potency test: The NIH potency test was carried out by the standard method described by Seligmann [7] . Briefly, groups of mice were vaccinated twice with dilutions of the proposed reference vaccine one week apart. One week after the second vaccination, the mice were challenged intracerebrally with the CVS strain of rabies virus containing between 5 and 50 LD 50 . The only mouse that died between the 5th and 14th days was considered to have died from rabies. The potency of the proposed reference vaccine was calculated to be a ratio of 50% effective dose (ED 50 ) of the proposed reference vaccine to that of 5th International Standard for Rabies Vaccine and is expressed in International Units (IU).
GP potency test: The GP potency test had been an official potency test for rabies vaccines for animal use in Japan until 1996. Ten guinea pigs were each inoculated subcutaneously with 0.5 ml of the test vaccine (20-fold dilution) and 10 were used as a control group. Three weeks after the vaccination, they were challenged with an intramasseteric injection of 10 LD 50 /0.2 ml of the CVS strain of rabies virus. After observation for 2 weeks, the survival rate of the each group was determined. Guinea pigs exhibiting signs of rabies infection were listed as dead. To pass the test, the survival rate has to exceed 70% in the test vaccine group and be no more than 20% in the control group. The potencies of the proposed reference vaccine undiluted and diluted 2 fold, 3 fold and 4 fold were evaluated by the GP potency test to estimate the potency of the proposed reference vaccine.
RESULTS
Neutralizing antibody responses in the dogs after vaccination:
The neutralizing antibody responses in the dogs are shown in Table 1 . The neutralizing antibody titers rose drastically in the first month and then continued to fall gradually until the 12th month after vaccination. No significant differences between the titers in the three groups were found at any time point after vaccination. The geometric means of the neutralizing antibody titers in the dogs injected with undiluted, 2-fold-diluted and 4-fold-diluted proposed reference were 12.1, 10.6 and 10.6, respectively. All the dilutions of the proposed reference vaccine were found to induce sufficient immunity for at least 12 months after vaccination, since the dogs with neutralizing antibody titers of 10 or more were able to endure the challenge as stated above.
NIH potency tests: NIH potency tests were carried out at four laboratories and were repeated twice or 3 times. The results of the tests are summarized in Table 2 . Based on the results, the IU of the proposed reference vaccine was 3.7.
GP potency tests:
The results of GP potency tests are summarized in Table 3 . The group injected with the undi- luted, the group injected with that diluted 2-fold, and the group injected with that diluted 3-fold passed the test, but the group injected with that diluted 4-fold did not pass the test.
Comparison of the results of potency test by ELISA with those of GP potency tests:
Thirteen lots of rabies vaccines that had been applied for the national assay in 1996 were used for both the potency test by ELISA and the GP potency test. As shown in Table 4 , the results of the potency test by ELISA and GP potency tests were the same for 12 (92.3%) of the 13 lots.
DISCUSSION
The purpose of this study was to establish a reliable potency test by ELISA for a rabies vaccine for animal use in Japan. We previously reported that an ELISA we had developed was suitable for a potency test, and we described a method for calculating the potency. In the present study, we standardized the reference vaccine used for determining the potencies of test vaccines and for confirming the reliability and reproducibility of the test. We evaluated the proposed reference vaccine by three methods, i.e., by the neutralizing antibody responses in dogs after vaccination, by the GP potency test, which is the earlier official potency test used in Japan, and by the NIH potency test, which is widely used throughout the world.
It was found that the proposed reference vaccine either undiluted or diluted 2 fold or diluted 4 fold was able to induce sufficient neutralizing antibodies for protection in dogs until at least 12 months after vaccination. The GP potency test indicated that the proposed reference vaccine diluted 3-fold was sufficient. The NIH potency test indicated that the IU of the proposed reference vaccine was 3.7 IU/dose. From these results and the WHO recommendation that veterinary rabies vaccines should have a potency of at least 1.0 IU per dose [9] , we decided to dilute the proposed reference vaccine by 3 fold and regarded it as the reference vaccine.
Based on the results of this study, the reference vaccine was standardized and the potency test by ELISA was established as the official potency test in Japan in 1996, replacing the earlier official potency test, the GP potency test.
Finally, we compared the results of the ELISA with those of the GP potency test. The results of the ELISA and GP potency test showed good agreement, but disagreement in the results was found in one lot, which passed the ELISA but not by the GP potency test. Considering that both the RP by the potency test by ELISA and the potency by the GP potency test were close to the threshold, the disagreement seemed to come from wide variation in the results of the GP potency test. The potency test established in this study is superior to challenge protection tests such as the NIH potency test and GP potency test in that there is only a small variation in test results, the use of animals is not required, a pathogenic live virus is not required, and a long period of time is not required. Therefore, this method enables control of the antigen content in the production process. This method should be useful for quality control of and stable production of rabies vaccines.
